Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
Authors
Keywords
-
Journal
JOURNAL OF VIRAL HEPATITIS
Volume 19, Issue 10, Pages 677-684
Publisher
Wiley
Online
2012-09-12
DOI
10.1111/jvh.12003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Protease Inhibitors for the Treatment of Chronic Hepatitis C
- (2013) Shan Liu et al. ANNALS OF INTERNAL MEDICINE
- Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin
- (2012) Y. Chen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
- (2012) Fred Poordad et al. GASTROENTEROLOGY
- Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C
- (2012) Tom W. Chu et al. GASTROENTEROLOGY
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
- (2012) Calogero Cammà et al. HEPATOLOGY
- 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
- (2012) K.V. Kowdlev et al. JOURNAL OF HEPATOLOGY
- 101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
- (2012) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
- (2012) M. Sulkowski et al. JOURNAL OF HEPATOLOGY
- 1113 ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
- (2011) M. Coto-Llerena et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
- (2011) Chen-Hua Liu et al. ANTIVIRAL THERAPY
- Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
- (2011) Alessandra Mangia et al. HEPATOLOGY
- IL28Bgenetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
- (2011) Amir Moghaddam et al. HEPATOLOGY
- Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
- (2011) Stella De Nicola et al. HEPATOLOGY
- 1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL
- (2011) P. Pockros et al. JOURNAL OF HEPATOLOGY
- 4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS
- (2011) R. Flisiak et al. JOURNAL OF HEPATOLOGY
- IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
- (2011) P.-Y. Bochud et al. JOURNAL OF HEPATOLOGY
- 1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT
- (2011) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- 13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
- (2011) S. Pol et al. JOURNAL OF HEPATOLOGY
- 1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
- (2011) I.M. Jacobson et al. JOURNAL OF HEPATOLOGY
- IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
- (2011) Tarik Asselah et al. JOURNAL OF HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients
- (2010) Norma I Rallón et al. AIDS
- Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C
- (2010) Albert Friedrich Stättermayer et al. Clinical Gastroenterology and Hepatology
- An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
- (2010) Alessandra Mangia et al. GASTROENTEROLOGY
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
- (2010) Alexander J. Thompson et al. GASTROENTEROLOGY
- Variants in IL28B in Liver Recipients and Donors Correlate With Response to Peg-Interferon and Ribavirin Therapy for Recurrent Hepatitis C
- (2010) Takasuke Fukuhara et al. GASTROENTEROLOGY
- A Polymorphism Near IL28B Is Associated With Spontaneous Clearance of Acute Hepatitis C Virus and Jaundice
- (2010) Hans L. Tillmann et al. GASTROENTEROLOGY
- Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
- (2010) Jason Grebely et al. HEPATOLOGY
- Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection
- (2010) Michael R. Charlton et al. HEPATOLOGY
- Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
- (2010) Ming-Lung Yu et al. HEPATOLOGY
- Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
- (2010) Christoph Sarrazin et al. JOURNAL OF HEPATOLOGY
- Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
- (2010) Tomokazu Kawaoka et al. JOURNAL OF HEPATOLOGY
- Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
- (2010) Dennis Eurich et al. LIVER TRANSPLANTATION
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- (2009) David L. Thomas et al. NATURE
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
- (2009) Vijayaprakash Suppiah et al. NATURE GENETICS
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
- (2009) Yasuhito Tanaka et al. NATURE GENETICS
- Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
- (2008) Peter Ferenci et al. GASTROENTEROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started